Company news

BeOne Medicines Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

June 26, 2025

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

June 25, 2025

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

June 12, 2025

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

June 11, 2025

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025

June 11, 2025

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

June 2, 2025

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

May 31, 2025

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

May 27, 2025

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

May 27, 2025

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

May 22, 2025

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

May 14, 2025

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

May 13, 2025

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

May 7, 2025

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

April 29, 2025

2024 Annual Report

April 28, 2025

Announcement on Convening the 2024 Annual Performance Briefing

April 18, 2025

BeiGene to Announce First Quarter 2025 Financial Results on May 7

April 17, 2025

Notice on Convening the 2025 Annual General Meeting

April 7, 2025

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

April 3, 2025

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

March 31, 2025

Announcement on Renewing Engagement of Audit Institution for 2025

March 24, 2025

Announcement on the Equity Registration Date for the 1st Extraordinary General Meeting in 2025

March 11, 2025

Notice on Convening the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2025

March 10, 2025

Indicative Announcement on Equity Change of Shareholders with Over 5% Shares Reaching 1%

March 6, 2025

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

March 4, 2025

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

February 27, 2025

BeiGene to Present at Upcoming Investor Conferences

February 25, 2025

Indicative Announcement on Equity Change of Shareholders with Over 5% Shares

February 24, 2025

Announcement on Voluntary Disclosure Regarding the Company's Earnings Call

February 13, 2025

Announcement on Nomination of the Board of Directors and Changes in Members of the Corporate Governance Committee

January 20, 2025

Announcement on the Equity Registration Date for the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2025

January 17, 2025

Announcement on Voluntary Disclosure of the Change of the Company's NASDAQ Stock Code

December 23, 2024

Announcement on Voluntary Disclosure of the Incorporation of Commercial Products for Multiple Indications into the New Catalogue of Drugs for Basic National Medical Insurance

November 28, 2024

Announcement on Proposed Change of Company's English Name

November 14, 2024

Announcement on Using Partial Extra Raised Funds to Supplement Current Capital Permanently

November 12, 2024

Announcement on Convening the Q3 2024 Performance Briefing

November 5, 2024

Announcement on the Death of the Independent Non-executive Director

October 28, 2024

Announcement on the Appointment of Independent Non-executive Directors and Members of Audit Committee of the Board of Directors

September 26, 2024

Announcement on the Equity Registration Date for the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2024

September 20, 2024

Semi-annual Report in 2024

August 29, 2024

Announcement on Convening Semi-annual Performance Briefing 2024

August 21, 2024

Announcement on Key Financial Data for the First Half Year of 2024

August 7, 2024

Announcement on Change of Senior Executive

July 18, 2024

Announcement on Key Financial Data of 1st Quarter of 2024

May 8, 2024

Notice on Convening 2024 Annual General Meeting

April 28, 2024

2023 Annual Report

April 26, 2024

Announcement on Voluntary Disclosure of European Commission's Approval of Baize'an (Tislelizumab Injection) for First-line and Second-line Treatment of Three Non-small Cell Lung Cancer Indications

April 23, 2024

Announcement on Convening 2023 Annual Performance Meeting

April 19, 2024

Announcement on Equity Registration Date of 2024 Annual General Meeting

March 28, 2024

Announcement on Appointing Member of Advisory Committee on Commercial and Medical Affairs of Board of Directors

March 21, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 21 decks. Every deck is listed under its year.